Cardiovascular Complications of Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Narrative Review

Overview

Journal Ann Geriatr Med Res

Specialty Geriatrics

Date 2021 Oct 6

PMID 34610666

Citations 7

Authors

Sara Young

Enoch Chung

Michael A Chen

Affiliations

Soon will be listed here.

Abstract

While acetylcholinesterase inhibitors are used to treat a wide range of patients with Alzheimer's disease, acetylcholinesterase inhibitor use has also been associated with a variety of cardiovascular complications, including bradycardia and syncope. Herein, we review the pathophysiology and clinical evidence for cardiovascular complications caused by acetylcholinesterase inhibitors in patients being treated for dementia and discuss options for their management.

Citing Articles

Aubl. Essential Oil: Chemical Composition, In Vitro Antioxidant Activity, and Inhibitory Effects of Acetylcholinesterase, α-Glucosidase and β-Lactamase.

Zhu X, Zhu J, Xu Z, Liu X Molecules. 2024; 29(12).

PMID: 38930934 PMC: 11206966. DOI: 10.3390/molecules29122869.

Galantamine-Induced Third-Degree Heart Block.

Katib H, Shah A, Yousaf H Cureus. 2024; 16(3):e55757.

PMID: 38586643 PMC: 10998973. DOI: 10.7759/cureus.55757.

Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.

Varadharajan A, Davis A, Ghosh A, Jagtap T, Xavier A, Menon A J Neurosci Rural Pract. 2023; 14(4):566-573.

PMID: 38059250 PMC: 10696336. DOI: 10.25259/JNRP_356_2023.

Cholinesterase inhibitors associated with lower rate of mortality in dementia patients with heart failure: a nationwide propensity weighting study.

Hsieh M, Lee C, Chen D, Wu C, Huang Y, Chang S Clin Auton Res. 2023; 33(6):715-726.

PMID: 37935929 DOI: 10.1007/s10286-023-00982-6.

Pacemaker Implants and Their Influence on the Daily Life of Patients with Dementia with Lewy Bodies: A Qualitative Case Study.

Heyman I, Brorsson A, Persson T, Londos E Neurol Ther. 2023; 12(4):1359-1373.

PMID: 37326788 PMC: 10310613. DOI: 10.1007/s40120-023-00513-5.

References

Xu H, Garcia-Ptacek S, Jonsson L, Wimo A, Nordstrom P, Eriksdotter M . Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology. 2021; 96(17):e2220-e2230. PMC: 8166426. DOI: 10.1212/WNL.0000000000011832. View

Calvo-Romero J, Ramos-Salado J . [Symptomatic sinus bradycardia associated with donepezil]. Rev Neurol. 1999; 28(11):1070-2. View

Farlow M, Salloway S, Tariot P, Yardley J, Moline M, Wang Q . Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther. 2010; 32(7):1234-51. PMC: 3068609. DOI: 10.1016/j.clinthera.2010.06.019. View

Cummings J, Isaacson R, Schmitt F, Velting D . A practical algorithm for managing Alzheimer's disease: what, when, and why?. Ann Clin Transl Neurol. 2015; 2(3):307-23. PMC: 4369281. DOI: 10.1002/acn3.166. View

Mueller C, Perera G, Hayes R, Shetty H, Stewart R . Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. Age Ageing. 2017; 47(1):88-94. DOI: 10.1093/ageing/afx098. View

Briggs R, Kennelly S, ONeill D . Drug treatments in Alzheimer's disease. Clin Med (Lond). 2016; 16(3):247-53. PMC: 5922703. DOI: 10.7861/clinmedicine.16-3-247. View

Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J . The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther. 2010; 88(3):335-8. PMC: 3120840. DOI: 10.1038/clpt.2010.98. View

colovic M, Krstic D, Lazarevic-Pasti T, Bondzic A, Vasic V . Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013; 11(3):315-35. PMC: 3648782. DOI: 10.2174/1570159X11311030006. View

Doody R, Ferris S, Salloway S, Sun Y, Goldman R, Watkins W . Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009; 72(18):1555-61. DOI: 10.1212/01.wnl.0000344650.95823.03. View

10.

Bhatti G, Reddy A, Reddy P, Bhatti J . Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease. Front Aging Neurosci. 2020; 11:369. PMC: 6966236. DOI: 10.3389/fnagi.2019.00369. View

11.

Bordier P, Lanusse S, Garrigue S, Reynard C, Robert F, Gencel L . Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging. 2005; 22(8):687-94. DOI: 10.2165/00002512-200522080-00005. View

12.

Kakinuma Y, Ando M, Kuwabara M, Katare R, Okudela K, Kobayashi M . Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Lett. 2005; 579(10):2111-8. DOI: 10.1016/j.febslet.2005.02.065. View

13.

Isik A, Soysal P, Stubbs B, Solmi M, Basso C, Maggi S . Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review. J Am Geriatr Soc. 2018; 66(9):1805-1811. DOI: 10.1111/jgs.15415. View

14.

He X, Zhao M, Bi X, Sun L, Yu X, Zhao M . Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol. 2014; 172(23):5489-500. PMC: 4667861. DOI: 10.1111/bph.13010. View

15.

Campbell N, Perkins A, Gao S, Skaar T, Li L, Hendrie H . Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. J Am Geriatr Soc. 2017; 65(7):1497-1504. PMC: 6604617. DOI: 10.1111/jgs.14827. View

16.

Lu Y, Liu J, Bi X, Yu X, Kong S, Qin F . Pyridostigmine ameliorates cardiac remodeling induced by myocardial infarction via inhibition of the transforming growth factor-β1/TGF-β1-activated kinase pathway. J Cardiovasc Pharmacol. 2014; 63(5):412-20. DOI: 10.1097/FJC.0000000000000062. View

17.

Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc J . Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf. 2007; 30(11):1063-71. DOI: 10.2165/00002018-200730110-00005. View

18.

Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M . Cholinergic symptoms and QTc prolongation following donepezil overdose. Am J Emerg Med. 2017; 35(9):1386.e1-1386.e3. DOI: 10.1016/j.ajem.2017.06.044. View

19.

Malik B, Hamid P, Khan S, Gupta D, Islam M . Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon. Cureus. 2020; 11(12):e6451. PMC: 6977576. DOI: 10.7759/cureus.6451. View

20.

Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M . The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013; 34(33):2585-91. DOI: 10.1093/eurheartj/eht182. View